Philadelphia, PA (USA) and Basel (CH), 20 November 2019 -- Navrogen Inc. and Lonza Pharma & Biotech announced today that they have entered a licensing agreement for the production of Navrogen's biotherapeutics using Lonza’s GS Xceed Expression System.
Philadelphia, PA, October 1, 2019 -- Navrogen, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at the U.S. National Cancer Institute (NCI). The CRADA is focused on advancing antibody-based experimental medicines to targets associated with tumor-mediated immuno-suppression.
Philadelphia, PA, September 17, 2019 -- Navrogen, Inc. announced today that it has raised $3.2M in convertible note financing to support its operations, Humoral Immuno-Oncology (HIO) discovery platform and preclinical therapeutic pipeline activities. The financing was led by Ben Franklin Technology Partners of South Eastern Pennsylvania and a number of private investors.
We at Navrogen are committed to finding solutions and applying them to next-generation biologicals. Finding these solutions is at the core our mission.